"1-Chloro-3-ethyl-pent-1-en-4-yn-3-ol"@en . "113-18-8"@en . . . . . . . "Symptoms of overdose include thrombocytopenia."@en . . . . . "Bayley, A. and McLamore, W.M.; U.S. Patent 2,746,900; May 22,1956; assigned to Chas. Pfizer & Co., Inc."@en . . "ethyl \u03B2-chlorovinyl ethynyl carbinol"@en . "3-(beta-chlorovinyl)-1-pentyn-3-ol"@en . "Rapidly absorbed from gastrointestinal tract."@en . "Placidyl"@en . "Humans and other mammals"@en . . . . . " "@en . "Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours."@en . . . . "Avoid alcohol"@en . "Used for short-term hypnotic therapy in the management of insomnia for periods of up to one week in duration; however, this medication generally has been replaced by other sedative-hypnotic agents."@en . "3-(\u03B2-chlorovinyl)-1-pentyn-3-ol"@en . . . . . "Take with food to reduce irritation."@en . . . "illicit"@en . . "withdrawn"@en . . . "approved"@en . . . . . . . . . "Although the exact mechanism of action is unknown, ethchlorvynol appears to depress the central nervous system in a manner similar to that of barbiturates. Barbiturates bind at a distinct binding sites associated with a Cl^- ionopore at the GABA_A receptor, increasing the duration of time for which the Cl^- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged."@en . . . "35-50%"@en . . "1-chloro-3-ethyl-1-penten-4-yn-3-ol"@en . . "Ethchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists. [Wikipedia]"@en . . . "Ethchlorvynol"@en . . . "\u03B2-chlorovinyl ethyl ethynyl carbinol"@en .